📌 Key Takeaways
- On June 9, 2026, Life Biosciences announced the first human dose of ER-100—
marking the world’s first clinical trial of Partial Epigenetic Reprogramming (PER) in a human patient. - ER-100 delivers three transcription factors—OCT4, SOX2, and KLF4 (OSK)—
via an AAV2 viral vector into retinal ganglion cells,
erasing epigenetic “aging records” to restore a youthful cellular state. - The FDA cleared the IND application in January 2026.
Phase 1 evaluates safety and tolerability,
with participants followed for up to five years. - The initial indication is ophthalmic—targeting glaucoma and NAION—
but Life Biosciences plans to expand the platform to age-related diseases across the body,
including skin, joints, cardiovascular, and neurological conditions. - Clinical access remains years away for most patients,
but June 9, 2026 marks the day aging treatment moved from science fiction
to human biology.
On June 9, 2026, Life Biosciences—co-founded by Harvard Professor Dr. David Sinclair—announced the first human administration of ER-100,
a drug designed to reverse the root causes of aging at the epigenetic level.
(Source: Life Biosciences Official Press Release, June 9, 2026)
The initial target indications are open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION).
But the significance of this trial extends far beyond ophthalmology.
For the first time in human history,
a therapy designed to treat aging itself has been administered to a living person.
INDEX
What Does “Reversing Aging” Actually Mean?
Your DNA sequence—the genetic code itself—does not change over your lifetime.
But how that DNA is read—which genes are switched on or off—shifts continuously with age.
This is epigenetics.
As we age, this “settings file” becomes corrupted,
and cells progressively lose their functional identity.
ER-100’s premise: reset that settings file to a younger state,
and the cell may function as if it were young again.
🔬 How ER-100 Works: “Four Factors, Minus One”
Yamanaka Factors (all four): OCT4 · SOX2 · KLF4 · c-MYC
Discovered in 2006 by Nobel laureate Dr. Shinya Yamanaka (Kyoto University),
these four proteins can reprogram any cell back into a pluripotent stem cell (iPSC).
The problem: using all four carries a significant cancer risk.
ER-100’s Innovation (OSK: three factors only): By omitting c-MYC,
ER-100 uses only OCT4, SOX2, and KLF4.
The cell retains its identity as a retinal ganglion cell,
while only its epigenetic “aging record” is erased and reset—
a process called partial reprogramming.
Why Start with Eye Disease?
Glaucoma and NAION both involve progressive damage to the optic nerve—specifically retinal ganglion cells.
Current treatments can slow progression by reducing intraocular pressure,
but once retinal ganglion cells are lost, they do not regenerate.
Vision loss is permanent.
Dr. Sinclair’s landmark 2020 paper in Nature opened a new door.
When OSK was administered to mice,
damaged optic nerves regenerated and age-related vision decline was reversed.
ER-100 is the direct clinical translation of that finding.
Why NERO Is Covering This: The Longevity Medicine Connection
ER-100 is, at this moment, an ophthalmic gene therapy.
It is not available at aesthetic clinics,
and regulatory approval in most markets remains years away.
But Life Biosciences has been explicit about its roadmap:
the epigenetic restoration platform is intended to expand
to skin, joints, cardiovascular disease, and neurological aging.
“Epigenetic clocks.” “Biological skin age.” “Reversing cellular aging.”
These are the same concepts now driving the frontier of aesthetic and longevity medicine.
ER-100 sits at the far end of that trajectory.
What happened on June 9, 2026 will be recorded as the day
aging treatment stopped being science fiction.
When Dr. Sinclair published his 2020 Nature paper,
most researchers filed it under “compelling animal data.”
On June 9, 2026, that data entered a living human body.
There is no direct clinical bridge to aesthetic medicine yet.
But the ambition to access the root cause of aging—
Sculptra, PDRN, exosomes, every regenerative therapy NERO has covered—
all point toward the same distant destination that ER-100 is now approaching.
The era of treating aging as a disease has begun.
Remember June 9, 2026.
Summary
- On June 9, 2026, Life Biosciences announced the world’s first human administration
of a Partial Epigenetic Reprogramming (PER) therapy. - ER-100 delivers OSK (OCT4, SOX2, KLF4)—Yamanaka factors minus c-MYC—
via AAV2 vector to erase epigenetic aging records in retinal ganglion cells. - Phase 1 targets glaucoma and optic nerve disease for safety validation,
with participants followed for up to five years. - Life Biosciences plans to expand the platform to skin, joints, cardiovascular, and neurological aging,
placing ER-100 on the frontier of longevity and aesthetic medicine.
Frequently Asked Questions
The Phase 1 trial is ongoing in the United States under FDA IND clearance.
No regulatory submissions have been made in other markets.
For updates, monitor Life Biosciences’ official communications.
Traditional gene therapy corrects or replaces a mutated DNA sequence.
ER-100 does not alter the DNA sequence itself—
it resets the pattern of gene expression (the epigenome) to a younger state.
This distinction is what allows cells to rejuvenate
without losing their specialized identity.
a pluripotent stem cell—which carries a meaningful cancer risk.
ER-100 omits c-MYC and uses only OSK (three factors),
achieving partial reprogramming: the cell’s aging record is erased,
but it retains its identity as a retinal ganglion cell.
This is the core safety innovation of the approach.
Sources
Life Biosciences. “Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies.” Official Press Release, June 9, 2026.
Life Biosciences. “Life Biosciences Announces FDA Clearance of IND Application for ER-100.” Official Press Release, January 28, 2026.
Lu Y, Brommer B, Tian X, et al. “Reprogramming to recover youthful epigenetic information and restore vision.” Nature 588:124–129, 2020. DOI: 10.1038/s41586-020-2975-4.
GlitchWire. “Life Biosciences Doses First Patient in Landmark Epigenetic Reprogramming Trial for Vision Loss.” June 2026.
AI Weekly. “Life Biosciences Doses First ER-100 Phase 1 Patient.” June 2026.
